X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-july-26-2023-55742.pdf
https://www.reuters.com/legal/us-supreme-court-rebuffs-novartis-bid-revive-ms-drug-gilenya-patent-2023-04-17/
https://www.fiercebiotech.com/biotech/vyne-swings-behind-bet-inhibitors-seeks-partner-failed-eczema-drug
https://www.fiercepharma.com/pharma/novartis-files-supreme-court-bid-gilenya-patent-case
https://endpts.com/supreme-court-rejects-novartis-request-for-stay-in-gilenya-patent-battle/
https://www.reuters.com/legal/us-supreme-court-rebuffs-novartis-allows-generic-versions-ms-drug-2022-10-13/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210252
https://endpts.com/novartis-takes-gilenya-fight-to-supreme-court-as-generic-competition-looms/
https://www.globenewswire.com/news-release/2022/09/21/2519779/0/en/Novartis-plans-to-petition-the-U-S-Supreme-Court-to-uphold-validity-of-the-Gilenya-fingolimod-dosing-regimen-patent.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208003
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212953
https://www.novartis.com/news/media-releases/novartis-announces-us-court-appeals-federal-circuit-cafc-upholds-validity-gilenya-fingolimod-dosage-regimen-patent
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212152
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207939
https://www.pharmacompass.com/pdf/news/mylans-fingolimod-mylan-fingolimodreceives-approval-in-europe-1632214941.pdf
https://www.ema.europa.eu/en/documents/overview/fingolimod-mylan-epar-medicine-overview_en.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207939
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207993
https://www.reuters.com/article/us-novartis-gilenya/u-s-court-upholds-patent-for-novartis-ms-drug-gilenya-idUSKCN25D2A0
https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/high-sero-prevalence-in-cities-indicate-indias-ifr-might-be-low-despite-doubts-about-under-reporting-of-deaths/articleshow/77620342.cms
https://www.novartis.com/news/media-releases/novartis-announces-us-district-court-district-delaware-upholds-validity-gilenya-fingolimod-dosage-regimen-patent
https://www.sciencedaily.com/releases/2020/08/200813142339.htm#:~:text=A%20multiple%20sclerosis%20drug%20may,and%20reduce%20the%20latent%20reservoir.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208008
https://www.ema.europa.eu/en/documents/assessment-report/fingolimod-accord-epar-public-assessment-report_en.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207971
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207985
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208559
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207933
https://www.fiercepharma.com/pharma/novartis-must-face-claims-it-fired-employee-for-raising-gilenya-kickback-scheme-concerns
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210252
https://www.fiercepharma.com/pharma/novartis-escapes-doctor-kickback-lawsuit-for-ms-blockbuster-gilenya
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208014
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207979
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207939
https://www.fiercepharma.com/pharma/fda-green-lights-3-generics-novartis-ms-star-gilenya-amid-legal-fight-to-keep-them-off
https://www.prnewswire.com/news-releases/fda-approves-first-generics-of-gilenya-300970299.html
https://endpts.com/jj-phiii-data-promise-drug-launch-into-crowded-ms-market/
https://www.clinicaltrialsarena.com/news/novartis-ofatumumab-phase-iii/
https://www.fiercepharma.com/pharma/novartis-repurposed-cancer-drug-arzerra-outpaces-sanofi-s-aubagio-multiple-sclerosis-trial
https://www.biopharmadive.com/news/multiple-sclerosis-drug-costs-skyrocketed-for-medicare-and-patients-study/561757/
https://www.ema.europa.eu/en/news/updated-restrictions-gilenya-multiple-sclerosis-medicine-not-be-used-pregnancy
https://www.thepharmaletter.com/article/lifemax-gains-rare-pediatric-status-for-netherton-syndrome-candidate-lm-030
https://www.thepharmaletter.com/article/still-strong-a-decade-on-gilenya-wins-approval-in-china
https://in.reuters.com/article/us-health-medicines-who/who-keeps-key-lung-cancer-drugs-off-its-essential-medicines-list-idINKCN1U40YS
Market Place
Share 
